February 09, 2009 -- Shire plc , announces that it has received Paragraph IV Notice letters from Barr Laboratories, Inc. and Mylan, Inc. dated 2 and 4 February 2009 respectively, advising in each case of the filing of an Abbreviated New Drug Application for a generic version of 500mg, 750mg and 1gm FOSRENOL(R), (lanthanum carbonate). Barr and Mylan has filed the para IV against all the patents listed in OB for lanthanum carbonate chewable tablet.
The details can be read here.
No comments:
Post a Comment